Fabio Gelsomino

机构：University of Modena and Reggio Emilia · ORCID：0000-0001-7979-4795

发表论文 156 篇 · 总被引 4874 次 · h-index 27

代表论文

• Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 60)
• Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist (2025 · Cancer Treatment Reviews · 被引 9)
• Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort (2024 · Journal of Clinical Medicine · 被引 8)
• First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. (2024 · Journal of Clinical Oncology · 被引 8)
• New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical Issues (2025 · International Journal of Molecular Sciences · 被引 7)
• Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer (2025 · Nature Communications · 被引 5)